Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Sinovac Files Annual Report on Form 20-F



                   Sinovac Files Annual Report on Form 20-F

PR Newswire

BEIJING, April 30, 2013

BEIJING, April 30, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a
leading provider of vaccine products in China, announced today that it has
filed its 2012 Annual Report on Form 20-F with the U.S. Securities and
Exchange Commission for the year ended December 31, 2012 on April 30, 2013.
 The Annual Report on Form 20-F is now available on the Company's website
under SEC Filing in the Investor Relations section.

The Company will provide a hard copy of its complete audited financial
statements to its shareholders upon request, free of charge.  Requests for a
hard copy of the 2012 Annual Report can be made through the Contact IR page in
the Investor Relations section of the Company's website by submitting complete
mailing details on the request form.

About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on research, development, manufacturing and commercialization of vaccines that
protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal
rabies vaccine.  In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for
the Chinese Central Government, pursuant to the government-stockpiling
program.  The Company is also the only supplier of the H5N1 pandemic influenza
vaccine to the government-stockpiling program.  Sinovac is developing a number
of new pipeline vaccines including vaccines for enterovirus 71 (against hand,
foot, and mouth disease), pneumococcal conjugate, pneumococcal
polysaccharides, varicella and rubella.  Sinovac sells its vaccines mainly in
China and exports selected vaccines to Mongolia, Nepal, and the Philippines.
Sinovac was also granted a license to commercialize seasonal flu vaccine in
Mexico.

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Contact:
Helen Yang/Chris Lee
Sinovac Biotech Ltd. 
Tel:  +86-10-8279-9659/ 9696
Fax:  +86-10-6296-6910 
Email: ir@sinovac.com

Investors 
Stephanie Carrington 
The Ruth Group 
Tel: +1-646-536-7017 
Email: scarrington@theruthgroup.com

Media 
Victoria Aguiar 
The Ruth Group 
Tel: +1-646-536-7013 
Email: vaguiar@theruthgroup.com 

SOURCE Sinovac Biotech Ltd.

Website: http://www.sinovac.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement